Looking over the results released by Novo Nordisk (NYSE: NVO) it feels like the company is treading water. The company continues to operate in highly competitive price sensitive markets. A perfect illustration of this comes from one of the slides in this morning’s presentation which stated
“For 2018, formulary negotiations with pharmacy benefit managers and managed care organisations in the US are progressing
Subject to the final outcome of these negotiations, average prices after rebates are expected to be lower compared with the levels in 2017, predominantly driven by the basal insulin segment
Market access is anticipated . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.